Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Jul 19, 2018 1:35pm

293 Views

Post# 28339748

RE:Just scooped up some shares this morning

I humbly disagree...
First off I think ATE is crazy undervalued - Price should be much higher.
However between now and Q1 2019 when we get results from next trial, I believe there will be some dips and its very possible to see this price again.
That is the nature of the game, this is a penny stock and undervalued.
I hope we never see this price again but I would not bet on that until end of year.
Come January 1, 2019, then I would agree we will never see a sub 0.40 price again.
I'm hoping by then I'll be saying we will never see a sub 1.00 price again.

Bullboard Posts

Debt-free cannabis company set for next stage of growth